Accumulating evidence indicates that reduction of inflammatory factors and/or inhibition of oxidative stress can significantly reduce TGFβ-mediated cardiac fibrosis in different heart diseases [51, 52]. This evidence concerns the gene TGFB1 and heart disorder.